Live
- Leaked! iPhone 17 Battery, Camera, Chipset, Design and Display Upgrades
- Kerala mulls increasing retirement age of govt employees to 57
- Credit, deposit growth now in line with each other in India: Report
- Very 'productive' meeting with PM Modi, says British PM Starmer
- Actor Satyadev in Bengaluru to promote Zebra movie
- Vijaya Chaitanya Palanki Leads the Development of Advanced Data Analytics Algorithms for Upsell Scoring, Churn Prediction, and Promotion Management
- Wanaparthy collector says Prajapalana Vijayotsava kaka yatra from 19 Nov to 7 Dec
- Hamas says security operation kills 20 aid truck looters
- Flipkart Mobiles Bonanza Sale: Top 5 Smartphone Deals with Great Discounts
- Supreme Court Issues Notices to YS Avinash Reddy in YS Viveka murder case
Aurobindo gets FDA nod for anti-seizures drug
City-based Aurobindo Pharma has received final approval from the US health regulator to manufacture and market Lacosamide tablets in American market. The tablets are used for treatment of partial-onset seizures.
Hyderabad: City-based Aurobindo Pharma has received final approval from the US health regulator to manufacture and market Lacosamide tablets in American market. The tablets are used for treatment of partial-onset seizures.
"The company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Lacosamide tablets, 50 mg, 100 mg, 150 mg and 200 mg," Aurobindo Pharma said.
The company is eligible for 180 days of generic drug shared exclusivity, it added. "The launch of this product will be based on the outcome of the litigation in the US Court with UCB," the pharma firm said. The product is generic version of drug firm UCB Inc's Vimpat tablets in the same strengths.
"The approved product has an estimated market size of $782 million for the twelve months ending February 2016, according to IMS. With this latest approval, the company has a total of 257 abbreviated new drug application (ANDA) approvals (221 final approvals including 11 from Aurolife Pharma LLC and 36 tentative approvals) from USFDA.
